GLP-1 Weight Loss Comes with an Exercise Gap
Two NIH-All of Us analyses found that people with obesity treated with GLP-1 weight-loss therapies showed reduced activity after starting treatment. One study reported steps dropping from 5,047 to 4,487 per day (−560 steps; P<.001) and a decline in moderate-to-vigorous activity from 27.9 to 22.2 minutes daily (−5.7 minutes; P<.001), with men and those reporting musculoskeletal pain showing larger declines. A separate single-time-point analysis of 298 GLP-1 users found a mean daily activity of about 204 minutes (roughly 24 minutes MVPA) and a mean 5,944 steps per day, with 57.7% not meeting the guideline of at least 150 minutes/week of MVPA and around 16 hours/day sedentary. The data suggest potential mechanisms—reduced energy availability, side effects, lean-mass loss—that may lower motivation to move, and a small case series linked high-dose tirzepatide to anhedonia-like symptoms that improved with dose reduction. Experts advocate pairing GLP-1 therapy with structured exercise support to maximize benefits, though findings are observational and limited by design and scope.
